{
  "image_filename": "table_p5_det_4_014.png",
  "image_path": "Treanor_et_al.__2011_/extracted/figures/table_p5_det_4_014.png",
  "image_type": "Table",
  "page_number": 5,
  "block_id": "det_4_014",
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "supports_claim": false,
  "explanation": "Table showing the number and percentage of influenza\u2010positive cases (CDC\u2010ILI and influenza\u2010positive illness, broken down by subtype A and B) in participants receiving FluBlok (recombinant vaccine) versus placebo, along with calculated vaccine efficacy (95% CI). does not support the claim because the table presents clinical efficacy data of a recombinant vaccine versus placebo and does not include antibody response measurements or comparisons to egg\u2010based standard\u2010dose vaccines. Note: Table is clear but limited to efficacy endpoints; no immunogenicity or egg\u2010based comparator data are provided.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Table showing the number and percentage of influenza\u2010positive cases (CDC\u2010ILI and influenza\u2010positive illness, broken down by subtype A and B) in participants receiving FluBlok (recombinant vaccine) versus placebo, along with calculated vaccine efficacy (95% CI).",
    "evidence_found": null,
    "reasoning": "does not support the claim because the table presents clinical efficacy data of a recombinant vaccine versus placebo and does not include antibody response measurements or comparisons to egg\u2010based standard\u2010dose vaccines.",
    "confidence_notes": "Table is clear but limited to efficacy endpoints; no immunogenicity or egg\u2010based comparator data are provided."
  }
}